Myriad misses Street

Molecular diagnostic company Myriad Genetics Inc. (NASDAQ:MYGN) reported fiscal 3Q10 diluted EPS from continuing operations of $0.33, missing by $0.06 the Street's estimate of $0.39 and down 13% from $0.38 in fiscal 3Q09. Revenues for the quarter were $90.8 million, up from $86.5 million in the prior year's quarter but below the Street's estimate of $97.8 million. Costs and expenses rose 12% to $57.6 million. The company expects fiscal 2010 revenue of $360-$365 million and diluted EPS of $1.30-$1.35. The Street was expecting fiscal 2010 EPS of $1.50 on revenues of $381.5 million. ...